Submission

Submission

Abstract submission is closed.

Late Breaking Abstract Submission will open on July 1.

Please note:
The late breaking abstract deadline is not intended as an extension of the abstract submission deadline. The content of the abstract should not have been previously published or presented at national or international meetings prior to ESID 2019.  

View the Abstract Topics

KEY DATES

Abstract Submission OpensJanuary 2019
Abstract Submission DeadlineTuesday, 30 April 2019, Midnight CET
Extended Abstract Submission DeadlineMonday, 6 April 2019, Midnight CET
Abstract Notification*End of June

 

*Note all efforts are made to send notification by the planned date. Should there be any delays with the selection process, revised date will be posted here

 

GUIDELINES

RULES FOR SUBMISSION
Please read the submission rules before submitting an abstract.

  • Abstracts must be submitted online via the website only.
    ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
  • Presentation Type: Abstracts may be submitted for oral, poster discussion or poster display presentation.
    The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

Limitations

  • The same person may submit up to 5 abstracts regardless of presenting author.
  • The same person may serve as presenting author on up to 5 abstracts.
  • Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the Early Registration Deadline will be scheduled for presentation and included for publication.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official meeting publications.
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • Abstracts that have been previously presented at another meeting may not be submitted.
  • Abstracts must be submitted in English.
    All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
  • Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
  • Publication Embargo: The abstract contents will be available 4 weeks prior to the meeting. Late Breaking abstracts will be available on the first day of the meeting.

GUIDELINES FOR SUBMISSION
Before you begin, please prepare the following information:

  • Presenting author’s contact details:
    -Full first and family name(s)
    – Email address
    – Affiliation details: department, institution / hospital, city state (if relevant), Country
    – Phone number
  • Author and co-authors’ details
  • Preferred Presentation type: oral, poster discussion or poster display
  • Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
  • Abstract text – limited to 250 words including acknowledgements. (Please Note: word count is affected when graphs/tables are included).
  • Abstract topic– select the abstract topic per the list of topics.
  • Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 1024(w) x 768(h) pixel. You may upload images in JPG, GIF or PNG format.
  • Abstracts should clearly state:
    Background and aims
    Methods
    Results
    Conclusions 
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • Click on the SUBMIT button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, changes will not be possible.
  • You will receive an abstract reference number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.

ABSTRACT SUBMITTERS’ DECLARATION
During abstract submission you will be asked to confirm that you agree to the following:

  • I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
  • Submission of the abstract constitutes my consent to publication (e.g. Conference website, programmes, other promotions, etc.)
  • As the Abstract Submitter, I warrant and represent that I am the sole owner or have the rights of all the information and content (“Content”) provided to The 2019 Meeting of the European Society for Immunodeficiencies and Kenes Group (Hereafter: “The Organisers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
  • As the Abstract Submitter, I grant the Organisers a royalty-free, perpetual, irrevocable nonexclusive licence to use, reproduce, publish, translate, distribute, and display the Content.
  • The Organisers reserve the right to remove from any publication an abstract that does not comply with the above.
  • I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.